Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-548 with Azacitidine in TP53-Mutant MDS
NCT04638309Phase 1Terminated
- Sponsor
- Aprea Therapeutics
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of APR-548 in myelodysplastic syndrome (MDS) (3 cohorts), sponsored by Aprea Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 28 days. Started Sep 2021; status: terminated.
02
Drugs
APR-548
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04638309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638309.